Efficacy and Safety of Tigecycline for Patients with Hospital-Acquired Pneumonia

• Published in: Chemotherapy (Basel) Vol. 61; no. 6; p. 323
• Main Authors: Xu, Li, Wang, Ya-Li, Du, Shuai, Chen, Lin, Long, Li-Hui, Wu, Yan
• Format: Journal Article
• Language: English
• Published: Switzerland 2016
• Subjects: Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - pharmacokinetics; Anti-Bacterial Agents - therapeutic use; Databases, Factual; Female; Half-Life; Hospitals; Humans; Male; Minocycline - adverse effects; Minocycline - analogs & derivatives; Minocycline - pharmacokinetics; Minocycline - therapeutic use; Odds Ratio; Pneumonia - drug therapy; Pneumonia - mortality; Pneumonia - pathology
• ISSN: 1421-9794
• DOI: 10.1159/000445425

Tigecycline is an antibiotic agent with a broad spectrum, which has an antibacterial effect against many multidrug-resistant organisms. However, its clinical efficacy in the treatment of hospital-acquired pneumonia (HAP) is disputed. In this report, a systematic review and meta-analysis were conducted to evaluate the efficacy and safety of tigecycline for the treatment of HAP. The primary outcome was the rate of clinical cure, and the secondary outcomes were mortality and adverse events (AEs). Four trials involving 1,234 patients were included. The standard-dose tigecycline and comparator groups did not differ significantly in their rates of clinical cure. However, high-dose tigecycline was more effective than standard-dose tigecycline or the comparators for the treatment of HAP. There was no significant difference in mortality between the standard-dose or high-dose regimen and the comparators. Although the safety profile of standard-dose tigecycline was similar to the comparators, the high-dose regimen exhibited more AEs compared with the other groups. High-dose tigecycline is efficient for the treatment of HAP but is associated with more AEs.